Botti G, Chiappetta G, D'Aiuto G, de Angelis E, De Matteis A, Montella M, Picone A, Cascione F
Istituto Nazionale dei Tumori, Fondazione G. Pascale, Napoli, Italy.
Tumori. 1993 Jun 30;79(3):214-8. doi: 10.1177/030089169307900312.
The aim of the present study was to determine, retrospectively, whether the immunohistochemical expression of two biologic markers of aggressively, P-glycoprotein (P-gp) and PCNA/cyclin (PCNA), could be related to response to chemotherapy and prognosis in locally advanced breast cancer.
PC 10 Mab was used to determine the proliferation index (PCNA) and C-219 Mab to determine P-gp in 25 locally advanced breast carcinomas subjected to preoperative chemotherapy with MDR-related drugs.
P-gp and PCNA were expressed in 76% and 100% of the tumors, respectively. No case of high P-gp expression was associated with good chemosensitivity, and all P-gp-negative cases showed the best chemotherapeutic response. P-gp and PCNA were both highly expressed in patients who developed local-regional or distant metastases. No recurrence was associated with a negative or low P-gp score.
Statistical analysis showed that high P-gp expression was related to a poor response to chemotherapy and a short disease-free survival. A high PCNA score was not found to be significant for predicting chemosensitivity or survival.
本研究旨在回顾性确定两种侵袭性生物学标志物，即P-糖蛋白（P-gp）和增殖细胞核抗原/细胞周期蛋白（PCNA）的免疫组化表达是否与局部晚期乳腺癌的化疗反应及预后相关。
采用PC 10单克隆抗体检测25例接受与多药耐药相关药物术前化疗的局部晚期乳腺癌的增殖指数（PCNA），采用C-219单克隆抗体检测P-gp。
P-gp和PCNA分别在76%和100%的肿瘤中表达。P-gp高表达病例均无良好的化疗敏感性，所有P-gp阴性病例化疗反应最佳。P-gp和PCNA在发生局部区域或远处转移的患者中均高表达。P-gp评分阴性或低者无复发情况。
统计分析表明，P-gp高表达与化疗反应差及无病生存期短相关。未发现高PCNA评分对预测化疗敏感性或生存期有显著意义。
